ViaCyte, Inc. announced in July 2014 that it had filed
its first Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes, and in August 2014 the IND was accepted, allowing clinical testing to commence.
Reykjavik, ICELAND, January 13, 2005 — deCODE genetics (Nasdaq: DCGN) has submitted an
investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for DG041, a novel, first - in - class, orally - administered small molecule for the treatment o
drug application (IND) to the U.S. Food and
Drug Administration (FDA) for DG041, a novel, first - in - class, orally - administered small molecule for the treatment o
Drug Administration (FDA) for DG041, a novel,
first - in - class, orally - administered small molecule for the treatment of...